Dalton Industries, DALT, Profile, Summary

Dalton Industries, DALT, Profile, Summary

Dalton Industries (DALT) , conducts research and development in the Visual FX, Games and Digital Content Creation industries. Over the years we worked on a variety of feature film, television and game productions creating pipelines, CG art and providing supervision and consultation services in these areas. Dalton aslo makes tools, both hardware and software for users who work in these areas, leveraging their knowledge and experience into commercial products.
Dalton Industries Inc., has been working with various tools and devices related to the Virtual Reality and Augmented Reality industries for the last 2 years.Yet our research efforts go back to the dawn of Virtual Reality in the early 1990s, building our own head mounted displays.
The company is currently working on two software products for commercial release that relate to the Oculus Rift Virtual Reality Head Mounted Display Device and Leap Motion’s Leap Controller for use with content creation packages popular in the Visual FX, Games, 3D Animation and Audio production industries.
Dalton Industries continue to invest in Research and Development with with software products as well, such as the highly acclaimed and heavily used UberCam for LightWave3D. Originally intended exclusively for our own use, UberCam is now one of our most successful tool based products sold through Liberty3d.com. This is a common pattern for us. We build these tools to help us in our work on productions for clients as well as our own projects eventually turning them into commercial products retailed to the industry.
From stereoscopic virtual cameras to character animation and modeling tools in Computer Graphics, our products are being used by artists worldwide. Chances are that if you are a fan of sci-fi and have been watching TV and movies over the last decade you have seen shots that were created using our tools and methodologies.
With the increasing dependence of productions on Visual Effects and Digital Content Creation Tools, Dalton is committed to Research and Development of next generation technology and products in these areas has never been greater.

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Want to get your company featured? or have questions/comments, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

Anavex Life Sciences, AVXL, Profile, Summary

Anavex Life Sciences |AVXL | Profile

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.

Neurological diseases (CNS): Anavex SIGMACEPTOR™-N program involves the discovery and development of original drug candidates, targeting neurological diseases such as Alzheimer’s disease, epilepsy, and depression. The company’s lead drug candidates exhibit high affinity and selectivity to sigma receptors and also synergistic action with other receptors, such as Muscarinic and NMDA, with strong evidence of anti-amnesic, neuroprotective, and anxiolytic properties.

Oncology: Anavex SIGMACEPTOR™-C program involves the discovery and development of original drug candidates targeting cancer. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells, without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as melanoma, prostate and pancreas, and neuropathic pain.

In addition, several series of sigma ligands currently at different stages of development, target stroke, diabetes, multiple sclerosis and Parkinson’s disease.

The Pipe Line

Anavex’s lead drug candidate ANAVEX 2-73 -targeting Alzheimer’s Disease- is in Phase 1 clinical trials. The company has also initiated scale-up manufacturing of ANAVEX 1-41 targeting a range of important CNS disorders, including depression and Alzheimer’s Disease. Three more of its compounds (for malignant melanoma, prostatic cancer and epilepsy) are expected to reach final preclinical stages in the near term.

Other early-stage preclinical research (see diagram) involves drug candidates that target diseases like depression, neuropathic pain and various types of cancer.

Source: Anavex, OxBridge Research, Daily Stock Deals

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

CSIQ, Canadian Solar, Summary, Profile

THE COMEBACK KID, CANADIAN SOLAR, CSIQ
Canadian Solar, is a Chinese solar manufacturer based in Canada. is one of the largest solar companies, a vertically integrated provider of ingots, wafers, solar cells, solar modules. The company has huge manufacturing capacity scattered across China and exports its products globally.
Canadian Solar provides one of the widest PV product lines, from 0.03W to 305W, it also offers customized PV products and OEM service around the world.
Once an investors darling now trading near 52WK Lows. Investors are warming up to CSIQ for good reasons, it is one of the Low cost Solar Panels producers in the World and could benefit from the consolidation in the industry. We think the stock at this level ($2.40-$2.45) is very attractive and could be a winner for short to medium term, keep an eye!
Don't miss the NEXT premium Alert!Sign-up, Get Alerts that MakeMoney!® we get compensated by the companies we feature. Always Read the full Disclosure/Disclaimer. Thanks

VELA, VelaTel Global, Summary, Profile

China Wireless Broadband play! VELA - VelaTel Global Communications is a small telecommunications carrier operating primarily in China and Peru. It focuses on the deployment of Wireless Broadband telecommunications networks. VELA controls approximately 34,000 kilometers of installed fiber optic cable and holds WBB licenses for 9 cities in Fujian Province in China, in addition, it provides Internet services in 26 other cities. Under valued, Highly Speculative, Short term play, Keep an eye! Don't miss the NEXT premium Alert!Sign-up, Get Alerts that MakeMoney!® we get compensated by the companies we feature. Always Read the full Disclosure/Disclaimer. Thanks

Hyper Solar, HYSR.OB, Profile, Summary

Simple Brilliance!
Hyper Solar turning Water into Natural Gas
Hyper Solar (HYSR) Inspired by photosynthetic processes this small emerging company has patented a process to turn water into natural gas, according to the press release. The company says unlike other approaches to hydrogen and methane production that may require high temperature and high-pressure systems their process occurs at normal pressure and temperature. CO2 + 4H2 –> CH4 + 2H2O

Abundant Free Fuel and Cheap Reactors: Hyper Solar Reactors are simple and could be built at low cost on vacant, non-productive land, producing massive amounts of carbon neutral methane that can be piped into the existing natural gas infrastructure for everyday use in homes, power plants, factories, and vehicles.
Additionally the byproducts extracted from waste-water can be used to make chemicals further reduce the production cost of renewable natural gas. HYSR is trading around $0.06 Cents and the company's Market Cap is under $10 Million Dollars. Highly Speculative, Short Term trading opportunity.
You are missing the Premium Alerts! Sign-up, Get Alerts that MakeMoney!® we get compensated by the companies we feature. Always Read the full Disclosure/Disclaimer. Thanks

MNI, McClatchy,profile,summary

The McClatchy Group is one of the oldest Newspaper publishing companies in the United States. It owns The Miami Herald, The Sacramento Bee, the Fort Worth Star-Telegram and many other well known newspapers. It owns 30 daily newspapers and approximately 43 non-dailies in 29 markets.

McClatchy (MNI) also owns a portfolio of digital assets, including 14.4% of CareerBuilder.com, an online job site; and 33.3% of HomeFinder.com, as well as 25.6% of Classified Ventures LLC that offers classified Websites, such as the auto Website, Cars.com and Apartments.com.
Highly Undervalued - Medium to Long Term play - Its IP and Digital Assets are not getting the valuation they deserve. Keep an eye!

CBRX, Columbia Labs. NEPT, Neptune Technologies

CBRX - Columbia Labs, is focused on development and commercialization of women’s healthcare and endocrinology products. It develops products by utilizing its bioadhesive drug delivery technologies.
The company offers bioadhesive vaginal gel products that provide solutions for infertility, pregnancy support, amenorrhea, gynecologic, and other medical conditions. Its products include CRINONE and PROCHIEVE, which are progesterone gels; and STRIANT, a testosterone buccal system. Bouncing back from 52WK LOWS.

NEPT - Neptune Technologies & Bioressources is a biotechnology company that makes products derived from marine biomasses for the nutraceutical, pharmaceutical, and cosmetic industries.
Neptune product prevents skin damages caused by chronic exposure to UV radiation; reduces the physical and emotional symptoms associated with premenstrual syndrome; provides relief from dysmenorrheal; controls hyperlipidemia by reducing the cholesterol levels; reduces chronic inflammation and osteoarthritis disease; and controls attention deficit hyperactivity disorders. Very Attractive, keep an eye!
You are missing the Premium Alerts! Sign-up, Get Alerts that MakeMoney!®
we get compensated by the companies we feature. Always Read the full Disclosure/Disclaimer. Thanks

AVII, Avi Bio Pharma, Profile, Summary

AVI Bio Pharma is a leader in RNA based technology, the company is developing a range of potential therapeutic compounds that target different types of RNA. Unlike most other RNA-based approaches, AVI’s technology has been used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate or up-regulate targeted genes or proteins.

This Bio-pharmaceutical company has several drugs in the pipeline, and strategic alliances with leading institutions and pharmaceutical firms. The company also has collaborative agreements with select academic, governmental and non-governmental organizations. Very Attractive, Medium to Long Term, Bouncing Back from 52WK Lows.
You are missing the Premium Alerts! Sign-up, Get Alerts that MakeMoney!® we get compensated by the companies we feature. Always Read the full Disclosure/Disclaimer. Thanks

VALV, Shengkai Innovations, XOMA, Xoma Ltd.

VALV - Shengkai Innovations makes ceramic valves and components for industrial. It provides ceramic valves in various categories, including gate valves, ball valves and adjustable cut-off valves.The company's primary customers are electric power, petrochemical, chemical, aluminum, and metallurgy industries. The company is expected to increase its global market share. Stock is bouncing back from 52WK lows, keep an eye!
XOMA – XOMA is a biopharmaceutical company, engaged in the development of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on products, such as LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn's disease.

XOMA products include HCD122, a human anti-CD40 antagonist antibody for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases in Phase I/II clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. Undervalued, Bouncing back from 52WK LOWS.
You are missing the Premium Alerts! Sign-up, Get Alerts that MakeMoney!® we get compensated by the companies we feature. Always Read the full Disclosure/Disclaimer. Thanks